NeuroAct Communication offers expert guidance to scientific communication.

  • Define a publication strategy: identify objectives, target audience, journals
  • Aid to effective presentation of pharmacological data
  • Experienced scientific writing and editing: research reports, posters, symposia

For more information Contact.


WAY-100635 has high selectivity for serotonin 5-HT1A versus dopamine D4 receptors.

Martel JC, Leduc N, Ormière AM, Faucillon V, Danty N, Culie C, Cussac D, Newman-Tancredi A.
Eur J Pharmacol. 2007 Nov 21;574(1):15-9. Epub 2007 Jul 13.

The serotonin 5-HT1A receptor antagonist WAY-100635 was recently reported to have potent agonist properties at dopamine D4 receptors (Chemel et al., 2006, Psychopharmacology 188, 244-251.). Herein WAY-100635 (pKi at human (h) serotonin 5-HT1A receptors=9.51; pKi at dopamine hD4.4 receptors=7.42) stimulated [35S]GTPgammaS incorporation in membranes of Chinese Hamster Ovary cells expressing dopamine hD4.4 receptors with only moderate potency and modest efficacy (pEC50=6.63; Emax=19% of dopamine). Moreover, in antagonism experiments, WAY-100635 had a much lower potency at dopamine hD4.4 receptors (pKB=7.09), than at serotonin h5-HT1A receptors (pKB=9.47). These data demonstrate that WAY-100635 has high selectivity for serotonin h5-HT1A versus dopamine hD4.4 receptors.